Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new research centre backed with £11 million from GSK will build open-source digital twins of organs for in-silico research to advance disease understanding and speed up development of new drugs.

Oxford skyline © University of Oxford Images / John Cairns Photography

The Modelling-Informed Medicine Centre (MiMeC), founded by the biopharma company GSK and the University of Oxford and Imperial College London, will provide a new UK hub for research in the rapidly growing field of data-driven mechanistic modelling.

The centre will create computer models or ‘digital twins’ of organs and diseases to better understand how diseases of the lungs, liver, kidneys and cartilage progress, to discover and develop drugs more quickly, and to target medicines more precisely.

The centre is backed by £11 million funding from GSK and multidisciplinary expertise spanning mathematics, data science, and experimentation from the founding partners.

The partners aim to support the life sciences community by bringing together advances across multiple disciplines in the field and training a new generation of research and development specialists who understand best practice in this emerging area of biomedical research. It will share its models on an open-source basis and build collaborations with further partners.

GSK plans to use the research to incorporate computational models of organs into its drug development pipeline within five years, aided by industrial placements it will provide to researchers from the centre.

The programme is led by Professor Helen Byrne and Professor Philip Maini at the University of Oxford, Professor Steven Niederer at Imperial College London, and Dr Anna Sher at GSK.

Read the full story on the University of Oxford website